目的 探讨非洛地平与缬沙坦对原发性高血压患者肾脏的保护作用.方法 将我院2011年2月至2012年3月收治的56例原发性高血压伴蛋白尿患者随机分为A组、B组,每组28例.A组给予非洛地平,B组给予缬沙坦,疗程为3个月,比较两组药物的治疗效果.结果 两组患者治疗后血压与治疗前相比,差异均有统计学意义(P＜0.01);但治疗后两组血压相比差异无统计学意义(P＞0.05);两组患者治疗后24 h蛋白尿与治疗前相比,差异均有统计学意义(P＜0.01);但治疗后两组24 h蛋白尿比较差异无统计学意义(P＞0.05).结论 非洛地平和缬沙坦均具有显著的降压作用,可保护原发性高血压患者肾脏功能,但非洛地平价格明显低于缬沙坦,有望成为广大基层医院原发性高血压的首选肾脏保护药物.%Objective To study the protective effects of felodipine and valsartan on patients with essential hypertension kidney. Methods Admitted to our hospital from February 2011 to March 2012,56 patients with essential hypertension associated with proteinuria were randomly divided into 2 groups,28 cases in each group. Group A was given felodipine, group B was given valsartan, the treatment course of the two groups was 3 months, the therapeutic effects of the two groups were compared. Results After treatment, the blood pressure and 24 h proteinuria of the two groups decreased significantly( P 0. 05 ). Conclusion Both felodipine and valsartan have significant antihypertensive and protective effects on kidney function in patients with essential hypertension, but the price of felodipine is significantly lower than that of valsartan, therefore, it is expected to become the preferred renoprotective drugs for majority of the primary hospital in hypertension.
展开▼
